Literature DB >> 18462583

Strongyloides stercoralis infection in the immunocompromised host.

Roshan Ramanathan1, Thomas Nutman.   

Abstract

Strongyloides stercoralis is an intestinal nematode acquired in the tropics or subtropics. Most often, it causes chronic, asymptomatic infection, but a change in immune status can increase parasite numbers, leading to hyperinfection syndrome, dissemination, and death if unrecognized. Corticosteroid use is most commonly associated with hyperinfection syndrome. Diagnosis of Strongyloides infection is based on serology and serial stool examinations for larvae. The treatment of choice for chronic, asymptomatic infection is oral ivermectin. Alternative pharmacologic agents include albendazole and thiabendazole. For hyperinfection syndrome, ivermectin remains the drug of choice, though therapy duration must be individualized with the end point being complete parasite eradication. Recurrent strongyloidiasis should prompt an evaluation for human T-cell lymphotropic virus type 1 coinfection. No test of cure is currently available, although immunoglobulin G antibody levels have been shown to decline within 6 months of successful treatment.

Entities:  

Year:  2008        PMID: 18462583      PMCID: PMC3401551          DOI: 10.1007/s11908-008-0019-6

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  48 in total

1.  Prevalence of Blastocystis hominis and Strongyloides stercoralis infection in Okinawa, Japan.

Authors:  Tetsuo Hirata; Hiroshi Nakamura; Nagisa Kinjo; Akira Hokama; Fukunori Kinjo; Nobuhisa Yamane; Jiro Fujita
Journal:  Parasitol Res       Date:  2007-08-24       Impact factor: 2.289

2.  Bronchial asthma associated with intestinal parasites.

Authors:  D C Tullis
Journal:  N Engl J Med       Date:  1970-02-12       Impact factor: 91.245

3.  Efficacy of stool examination for detection of Strongyloides infection.

Authors:  Y Sato; J Kobayashi; H Toma; Y Shiroma
Journal:  Am J Trop Med Hyg       Date:  1995-09       Impact factor: 2.345

4.  A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis.

Authors:  P H Gann; F A Neva; A A Gam
Journal:  J Infect Dis       Date:  1994-05       Impact factor: 5.226

5.  Strongyloides stercoralis. The cause of an urticarial-like eruption of 65 years' duration.

Authors:  P M Leighton; H M MacSween
Journal:  Arch Intern Med       Date:  1990-08

6.  High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis.

Authors:  A S Gabet; F Mortreux; A Talarmin; Y Plumelle; I Leclercq; A Leroy; A Gessain; E Clity; M Joubert; E Wattel
Journal:  Oncogene       Date:  2000-10-12       Impact factor: 9.867

7.  A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children.

Authors:  H Marti; H J Haji; L Savioli; H M Chwaya; A F Mgeni; J S Ameir; C Hatz
Journal:  Am J Trop Med Hyg       Date:  1996-11       Impact factor: 2.345

8.  High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees.

Authors:  Drew L Posey; Brian G Blackburn; Michelle Weinberg; Elaine W Flagg; Luis Ortega; Marianna Wilson; W Evan Secor; Kolby Sanders-Lewis; Kimberly Won; James H Maguire
Journal:  Clin Infect Dis       Date:  2007-10-11       Impact factor: 9.079

9.  Impairment of host immune response against strongyloides stercoralis by human T cell lymphotropic virus type 1 infection.

Authors:  Tetsuo Hirata; Nobufumi Uchima; Kazuto Kishimoto; Osamu Zaha; Nagisa Kinjo; Akira Hokama; Hiroshi Sakugawa; Fukunori Kinjo; Jiro Fujita
Journal:  Am J Trop Med Hyg       Date:  2006-02       Impact factor: 2.345

Review 10.  Evaluation and differential diagnosis of marked, persistent eosinophilia.

Authors:  Thomas B Nutman
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

View more
  24 in total

1.  Dexamethasone effects in the Strongyloides venezuelensis infection in a murine model.

Authors:  Eleuza R Machado; Daniela Carlos; Carlos A Sorgi; Simone G Ramos; Daniela I Souza; Edson G Soares; Julia M Costa-Cruz; Marlene T Ueta; David M Aronoff; Lúcia H Faccioli
Journal:  Am J Trop Med Hyg       Date:  2011-06       Impact factor: 2.345

Review 2.  Therapeutic approaches to patients with hypereosinophilic syndromes.

Authors:  Hans-Uwe Simon; Amy Klion
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

3.  Reducing the risk of infection in a 74-year-old man who is to receive prednisone.

Authors:  Daniel M Shafran; Paul E Bunce; Wayne L Gold
Journal:  CMAJ       Date:  2014-07-14       Impact factor: 8.262

4.  Methylprednisolone acetate induces, and Δ7-dafachronic acid suppresses, Strongyloides stercoralis hyperinfection in NSG mice.

Authors:  John B Patton; Sandra Bonne-Année; Jessica Deckman; Jessica A Hess; April Torigian; Thomas J Nolan; Zhu Wang; Steven A Kliewer; Amy C Durham; James J Lee; Mark L Eberhard; David J Mangelsdorf; James B Lok; David Abraham
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-04       Impact factor: 11.205

Review 5.  Innate and adaptive immunity to the nematode Strongyloides stercoralis in a mouse model.

Authors:  Sandra Bonne-Année; Jessica A Hess; David Abraham
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

6.  Improved diagnosis of Strongyloides stercoralis using recombinant antigen-based serologies in a community-wide study in northern Argentina.

Authors:  Alejandro J Krolewiecki; Roshan Ramanathan; Valeria Fink; Isabel McAuliffe; Silvana P Cajal; Kimberly Won; Marisa Juarez; Adriana Di Paolo; Laura Tapia; Norma Acosta; Rogan Lee; Patrick Lammie; David Abraham; Thomas B Nutman
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

7.  Immunization with the recombinant antigen Ss-IR induces protective immunity to infection with Strongyloides stercoralis in mice.

Authors:  David Abraham; Jessica A Hess; Rojelio Mejia; Thomas J Nolan; James B Lok; Sara Lustigman; Thomas B Nutman
Journal:  Vaccine       Date:  2011-08-19       Impact factor: 3.641

8.  High rate of strongyloidosis infection, out of endemic area, in patients with eosinophilia and without risk of exogenous reinfections.

Authors:  Silvia A Repetto; Pablo A Durán; María B Lasala; Stella M González-Cappa
Journal:  Am J Trop Med Hyg       Date:  2010-06       Impact factor: 2.345

9.  Strongyloidiasis hyperinfection in a patient with a history of systemic lupus erythematosus.

Authors:  Evan E Yung; Cassie M K L Lee; Joshua Boys; Daniel J Grabo; James L Buxbaum; Parakrama T Chandrasoma
Journal:  Am J Trop Med Hyg       Date:  2014-08-04       Impact factor: 2.345

10.  Prevalence of Strongyloides stercoralis in an urban US AIDS cohort.

Authors:  Linda Nabha; Sonya Krishnan; Roshan Ramanathan; Rojelio Mejia; Gregg Roby; Virginia Sheikh; Isabel McAuliffe; Thomas Nutman; Irini Sereti
Journal:  Pathog Glob Health       Date:  2012-08       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.